[MOL] A New Option for patients with relapsed indolent NHL.... [00319] Medicine On Line

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

[MOL] A New Option for patients with relapsed indolent NHL....

RITUXIMAB IS A NEW OPTION FOR PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN'S
LYMPHOMA
The survival rate 1 year after treatment with rituximab, the first
monoclonal antibody approved for cancer treatment in the United States, was
90% to 95%.
Drugs and Ther Perspect 14(5):1-5, 1999
http://oncology.medscape.com/13584
Warmly, lillian
 
We invite you to take a look at our Album.                                               
www.angelfire.com/sc/molangels/index.html
 
  ( Very informational, good tips, Molers pictures, art work and much more....